Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer
The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeut...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/11/2/149 |
id |
doaj-2eff6104440d40babffc357a89ebff50 |
---|---|
record_format |
Article |
spelling |
doaj-2eff6104440d40babffc357a89ebff502021-02-20T00:04:18ZengMDPI AGJournal of Personalized Medicine2075-44262021-02-011114914910.3390/jpm11020149Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian CancerChristen A. Khella0Gaurav A. Mehta1Rushabh N. Mehta2Michael L. Gatza3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USARutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USARutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USARutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USAThe underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeutic response, and clinical outcome. Recent advances in high-throughput proteogenomic profiling of tumor samples have resulted in the identification of novel oncogenic drivers, tumor suppressors, and signaling networks; biomarkers for the prediction of drug sensitivity and disease progression; and have contributed to the development of novel and more effective treatment strategies. In this review, we will focus on the impact of historical and recent advances in single platform and integrative proteogenomic studies in breast and ovarian cancer, which constitute two of the most lethal forms of cancer for women, and discuss the molecular similarities of these diseases, the impact of these findings on our understanding of tumor biology as well as the clinical applicability of these discoveries.https://www.mdpi.com/2075-4426/11/2/149genomicsproteomicsbreastovariancancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Christen A. Khella Gaurav A. Mehta Rushabh N. Mehta Michael L. Gatza |
spellingShingle |
Christen A. Khella Gaurav A. Mehta Rushabh N. Mehta Michael L. Gatza Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer Journal of Personalized Medicine genomics proteomics breast ovarian cancer |
author_facet |
Christen A. Khella Gaurav A. Mehta Rushabh N. Mehta Michael L. Gatza |
author_sort |
Christen A. Khella |
title |
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer |
title_short |
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer |
title_full |
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer |
title_fullStr |
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer |
title_full_unstemmed |
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer |
title_sort |
recent advances in integrative multi-omics research in breast and ovarian cancer |
publisher |
MDPI AG |
series |
Journal of Personalized Medicine |
issn |
2075-4426 |
publishDate |
2021-02-01 |
description |
The underlying molecular heterogeneity of cancer is responsible for the dynamic clinical landscape of this disease. The combination of genomic and proteomic alterations, including both inherited and acquired mutations, promotes tumor diversity and accounts for variable disease progression, therapeutic response, and clinical outcome. Recent advances in high-throughput proteogenomic profiling of tumor samples have resulted in the identification of novel oncogenic drivers, tumor suppressors, and signaling networks; biomarkers for the prediction of drug sensitivity and disease progression; and have contributed to the development of novel and more effective treatment strategies. In this review, we will focus on the impact of historical and recent advances in single platform and integrative proteogenomic studies in breast and ovarian cancer, which constitute two of the most lethal forms of cancer for women, and discuss the molecular similarities of these diseases, the impact of these findings on our understanding of tumor biology as well as the clinical applicability of these discoveries. |
topic |
genomics proteomics breast ovarian cancer |
url |
https://www.mdpi.com/2075-4426/11/2/149 |
work_keys_str_mv |
AT christenakhella recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer AT gauravamehta recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer AT rushabhnmehta recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer AT michaellgatza recentadvancesinintegrativemultiomicsresearchinbreastandovariancancer |
_version_ |
1724260062274256896 |